Equities

Shanghai Shen Lian Biomedical Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Shen Lian Biomedical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)9.66
  • Today's Change0.06 / 0.63%
  • Shares traded2.87m
  • 1 Year change+74.05%
  • Beta1.6089
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Shen Lian Biomedical Corp is a China-based company principally engaged in the research, development, production and sale of veterinary biological products. The Company’s core business includes the research, development, production and sale of animal vaccines, pharmaceuticals and veterinary diagnostic products. The Company’s main products include genetically engineered subunit vaccine for classical swine fever and live pseudorabies vaccine for porcine pseudorabies, which can be used to prevent classical swine fever and pseudorabies. The Company distributes its products within the domestic market.

  • Revenue in CNY (TTM)292.81m
  • Net income in CNY-30.34m
  • Incorporated2001
  • Employees391.00
  • Location
    Shanghai Shen Lian Biomedical CorpNo. 48Jiangchuan East Road, Minhang DistrictSHANGHAI 200241ChinaCHN
  • Phone+86 2 161255101
  • Fax+86 2 161267296
  • Websitehttp://www.slbio.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang Cheng Yi Pharmaceutical Co Ltd790.86m226.35m3.79bn738.0016.552.87--4.790.69970.69972.464.040.45081.9520.88--13.0211.4815.8714.0368.9969.0228.8824.630.985--0.080837.226.360.954623.218.84-20.0911.39
Henan Taloph Pharmaceutical Stock Co Ltd1.79bn46.95m3.83bn2.21k75.582.41--2.140.08840.08843.312.780.47912.741.60807,429.601.450.32413.130.610523.4526.223.020.63310.90381.860.359252.82-6.218.1616.002.61-19.14--
Shanghai Shen Lian Biomedical Corp292.81m-30.34m3.97bn391.00--2.81--13.55-0.0739-0.07390.7133.430.18641.420.9144748,865.90-2.213.53-2.403.8057.3673.49-11.8716.933.64--0.010643.520.63943.63-241.95---3.99--
Zhejiang Shouxiangu Pharmaceuticl Co Ltd649.78m132.39m4.10bn1.12k30.961.77--6.310.6680.6683.3011.660.20930.62228.34581,201.904.268.884.8610.3578.2983.0120.3728.553.19--0.198445.94-11.814.81-31.347.1240.840.3458
Shanghai MicuRx Pharmaceutical Co Ltd136.70m-342.96m4.12bn188.00--15.99--30.15-0.5197-0.51970.20770.39290.1610.46613.95727,105.00-40.40-31.40-53.04-35.4184.2682.42-250.89-503.672.15-406.300.5862--43.51---4.65--51.72--
Data as of Feb 13 2026. Currency figures normalised to Shanghai Shen Lian Biomedical Corp's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.94%Per cent of shares held by top holders
HolderShares% Held
China Asset Management Co., Ltd.as of 30 Jun 20251.88m0.74%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 20251.34m0.53%
Gfund Management Co., Ltd.as of 30 Jun 2025662.81k0.26%
Hongde Fund Management Co., Ltd.as of 30 Jun 2025290.60k0.12%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2025151.60k0.06%
E Fund Management Co., Ltd.as of 30 Jun 2025142.80k0.06%
Penghua Fund Management Co., Ltd.as of 30 Jun 2025126.25k0.05%
Huashang Fund Management Co., Ltd.as of 30 Jun 2025117.60k0.05%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 202593.78k0.04%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202593.37k0.04%
More ▼
Data from 30 Jun 2025 - 30 Nov 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.